UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 276

Sortiert nach

The Fracking Boom, Labor Structure, and Adolescent Fertility

Population research and policy review, 2022-10, Vol.41 (5), p.2211-2231

Owen, Andrew L.

2022

Volltextzugriff (PDF)

Publish rates of health gain resulting from treatment

BMJ (Online), 2014-10, Vol.349, p.g6026

Vallance-Owen, Andrew J

2014

Volltextzugriff (PDF)

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S490-S497

2022

Volltextzugriff (PDF)

Urban Scale Shifts since the Bronze Age: Upsweeps, Collapses, and Semiperipheral Development

Social science history, 2015-07, Vol.39 (2), p.175-200

2015

Volltextzugriff (PDF)

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S502-S509

2022

Volltextzugriff (PDF)

Prospects for Long-Acting Treatments for Hepatitis C

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S525-S529

2022

Volltextzugriff (PDF)

A living WHO guideline on drugs for covid-19

BMJ (Online), 2020-09, Vol.370, p.m3379

2020

Volltextzugriff (PDF)

The real reasons for measuring patient reported outcomes

BMJ (Online), 2013-12, Vol.347, p.f7437

Vallance-Owen, Andrew J

2013

Volltextzugriff (PDF)

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

The Journal of infectious diseases, 2019-05, Vol.219 (11), p.1735-1742

2019

Volltextzugriff (PDF)

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Clinical infectious diseases, 2012-03, Vol.54 (5), p.724-732

2012

Volltextzugriff (PDF)

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Clinical infectious diseases, 2019-01, Vol.68 (3), p.446-452

2019

Volltextzugriff (PDF)

Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S510-S516

2022

Volltextzugriff (PDF)

A living WHO guideline on drugs to prevent covid-19

BMJ (Online), 2021-03, Vol.372, p.n526

2021

Volltextzugriff (PDF)

Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

The Journal of infectious diseases, 2015-06, Vol.211 (suppl 3), p.S115-S125

2015

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Clinical infectious diseases, 2018-08, Vol.67 (5), p.785-790

2018

Volltextzugriff (PDF)

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Clinical infectious diseases, 2009-06, Vol.48 (11), p.e108-e116

2009

Volltextzugriff (PDF)

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Clinical infectious diseases, 2015-08, Vol.61 (3), p.453-463

2015

Volltextzugriff (PDF)

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

Clinical infectious diseases, 2022-08, Vol.75 (1), p.3-10

2022

Volltextzugriff (PDF)

Measuring patient care: PROMs promote health gain and patient involvement

BMJ (Online), 2008-02, Vol.336 (7640), p.344

Vallance-Owen, Andrew J

2008

Volltextzugriff (PDF)

Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials

BMJ (British Medical Journal), 2007-11, Vol.335 (7626), p.925-928

International edition, 2007

Volltextzugriff (PDF)

Outcome monitoring to facilitate clinical governance; experience from a national programme in the independent sector

Journal of public health (Oxford, England), 2004-06, Vol.26 (2), p.187-192

2004

Volltextzugriff (PDF)

Genetic Variants of "ABCC10", a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

The Journal of infectious diseases, 2011-07, Vol.204 (1), p.145-153

2011

Volltextzugriff (PDF)

Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir

Clinical infectious diseases, 2008-11, Vol.47 (9), p.1222-1225

2008

Volltextzugriff (PDF)

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Clinical infectious diseases, 2015-04, Vol.60 (7), p.1026-1032

2015

Volltextzugriff (PDF)

Interpreting arterial blood gas results

BMJ (Online), 2013-01, Vol.346, p.f16

2013

Volltextzugriff (PDF)

1 – 25 von 276

Suche als RSS-Feed

Aktive Filter

KollektionJstor Complete Legacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(260)
Mit Volltextzugriff
(261)

Publikationsform

Artikel
(256)
Reviews
(20)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(174)
Life Sciences & Biomedicine
(94)
Humans
(79)
Multidisciplinary Sciences
(74)
Science & Technology - Other Topics
(74)
Male
(40)
Female
(39)
Animals
(32)
Ecology
(32)
Environmental Sciences & Ecology
(31)
Biological Sciences
(30)
Infectious Diseases
(24)
Biological And Medical Sciences
(23)
Immunology
(23)
Microbiology
(22)
Adult
(21)
Social Sciences
(20)
Extraterrestrial Geology
(18)
Climate Change
(17)
Mars
(17)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Fracking Boom, Labor Structure, and Adolescent Fertility

Publish rates of health gain resulting from treatment

A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm

Urban Scale Shifts since the Bronze Age: Upsweeps, Collapses, and Semiperipheral Development

The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

Prospects for Long-Acting Treatments for Hepatitis C

A living WHO guideline on drugs for covid-19

The real reasons for measuring patient reported outcomes

Predicting Drug–Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals

Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment

A living WHO guideline on drugs to prevent covid-19

Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research

Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments

Measuring patient care: PROMs promote health gain and patient involvement

Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials

Outcome monitoring to facilitate clinical governance; experience from a national programme in the independent sector

Genetic Variants of "ABCC10", a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

Association of a Single-Nucleotide Polymorphism in the Pregnane X Receptor (PXR 63396C→T) with Reduced Concentrations of Unboosted Atazanavir

Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial

Interpreting arterial blood gas results

Aktive Filter

Suchergebnisse filtern